Effect of recombinant human type Ⅱ tumor necrosis factor-αreceptor antibody fusion protein on serum ESR and CRP in patients with ankylosing spondylitis
10.3969/j.issn.1005-1678.2017.03.026
- VernacularTitle:注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白对强直性脊柱炎患者血清ESR及CRP的影响
- Author:
Yuanlin XU
;
Junsong WU
- Keywords:
recombinant human tumor necrosis factor-αreceptorⅡ: IgG fc fusion protein for injection;
ankylosing spondylitis;
clinical efficacy;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(3):92-94
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the research of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection in the treatment of patients with ankylosing spondylitis in serum ESR and CRP.Methods 48 cases of patients with ankylosing spondylitis from October 2013 to October 2015 in our hospitol were randomly divided into the control group and treatment group , 24 cases in each group.The control group was treated with sulfasalazine enteric-coated Tablets orally, 1.0 g/time,bid;the experimental group was treated with rhTNFR:Fc for subcutaneous injection, 25 mg/time, two times/week.erythrocyte sedimentation rate (ESR), serum C reactive protein (CRP) level, efficiency of treatment and safety of two groups were compared before and after treatment.Results After treatment, compared with the control group, the ESR and the serum level of CRP were lower in the experimental group (P<0.05); the treatment efficiency of the experimental group 95.84% was significantly higher than that of the control group 75.00% (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The rhTNFR:Fc can significantly reduce the ESR and the serum level of CRP in patients with ankylosing spondylitis, improve clinical symptoms,the clinical efficacy and safety were high.
